New Points of Departure for More Global Influenza Vaccine Use

Irina Kiseleva

doi:10.3390/vaccines8030410

New Points of Departure for More Global Influenza Vaccine Use

Vaccines (Basel). 2020 Jul 23;8(3):410. doi: 10.3390/vaccines8030410.

Author

Irina Kiseleva^{1

2}

Affiliations

¹ Department of Virology, Federal State Budgetary ScYientific Institution, Institute of Experimental Medicine, 197376 St Petersburg, Russia.
² Faculty of Dental Medicine and Medical Technologies, St Petersburg University, 199034 St Petersburg, Russia.

Abstract

Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.

Keywords: COVID-19 pandemic; cross protectivity; inactivated vaccines; influenza; live attenuated vaccines; next-generation vaccines; synthetic vaccines.

Publication types

Editorial